Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA studyShunichi Sugawara, Yuichiro Ohe, Kazuhiko Nakagawa et al.|International Journal of Clinical Oncology|2022Cited by 6
Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort.Masashi Kondo, Kazuhiko Nakagawa, Shunichi Sugawara et al.|Journal of Clinical Oncology|2021Cited by 4
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trialsD. Ross Camidge, Sanjay Popat, Shunichi Sugawara et al.|Lung Cancer|2025Cited by 3